Rondol nomminiert für den "Ubistart Award"10 Dez 2014
The renowned Galien foundation and Ubifrance, the French agency for international business development, joined their forces and created this year the Ubistart award in order to recognize and reward small companies that develop worldwide innovation and collaborations in the field of healthcare.
300 companies applied when the competition started in April. Out of those 300, the 50 best projects combining scientific innovation, social improvement and economic efficiency have been selected and the project owners have been invited to pitch for partnering with US academic institutions and industrial groups at the inspiring New York Academy of Sciences in July.
Since July, Rondol has developed fruitful discussions with the University of Strasbourg School of Pharmacy, the Massachusetts Institute of Technology Novartis Center for Continuous Manufacturing and the Dow Chemicals Department for Pharmaceutical Polymers in order to develop a new small scale extrusion line fully fitted for the pharmaceutical industry.
Our project Lafayette has now been reviewed by the astonishing Ubistart jury consisting of Bernard Poussot, President of the Jury and Chairman of Wyeth Pharmaceutical, Mikael Dolstein, Head of R&D World at Pfizer, Jean Pierre Garnier, former CEO of GSK, Franz Humer, former Chairman at Roche, Sidney Taurel, former CEO at Eli Lilly and Elias Zeerhouni, Head of R&D World at Sanofi.
And we are very proud to announce that we have been nominated to this award - in the last 9 out of the initial 300 applicants - and that we had the opportunity to present our project at the Galien Ubistart award ceremony in Monaco on December 4th.
Prof. Victoire de Margerie, Rondol Chairman, looks back on this great experience and states: "Rondol is a pioneer in developing small scale extrusion and calendaring technologies for pharma applications. Collaborating with the University of Strasbourg, MIT Novartis and Dow Chemicals is a unique opportunity for us to bring to market the best equipment and convince the industry to speed up the use of extrusion so as to improve the bioavailability and efficiency of some key drugs while making possible the dispensing of these drugs by home care protocols - and more home care meaning of course improved patient comfort and lower treatment costs."